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Over the last few years considerable changes have occured in the concepts about
pharmacological treatment of congestive heart failure (CHF). In the sixties diuretics (and
digoxine) had been mainly used, whereas since the seventies the field had long been
dominated by the haemodynamic concept, stressing the importance of vasodilation.
Because vasoconstriction is present in CHF, vasodilators were introduced. Reduction
of pre- and afterload seemed beneficial for patients with CHF. Indeed in 1986 the
V-HeFT (I) study showed that treatment with hydralazine combined with isosorbide
dinitrate resulted in a reduction in mortality in patients with CHF. However, in the same
study, prazosin, an even more potent vasodilator, had an adverse effect. Another class of
drugs, the phosphodiesterase inhibitors, which were initially considered as promising
drugs in the treatment of CHF thanks to their favorable hemodynamic profile: they
combine vasodilating properties with positive inotropic effects, showed a considerable
increase in mortality in longterm studies, for example the PROMISE study with
milrinone. One of the factors that may contribute to this adverse effect is neurohumoral
activation.
Late in the eighties it appeared that ACE inhibitors (ACEI), drugs that combine
favorable haemodynamic effects with a decrease in neurohumoral activation, not only
reduced symptoms in patients with CHF, but also could improve survival. They now have
become the cornerstone in the treatment of CHF. ACEI have an inhibitory effect not only
on the renin-angiotensin-aldosterone-system (RAAS), but also on the sympathetic nervous
system (SNS). Beta blockers, which sometimes have adverse effects during acute CHF,
may improve exercise tolerance and perhaps survival during chronic treatment of CHF.
Thus, the hemodynamic hypothesis has lost ground to the socalled neurohumoral concept,
which states that during chronic treatment of CHF an inhibitory effect of the RAAS and
SNS may be more important than the hemodynamic effect.
In the light of this shift in paradigmas of CHF treatment, it is interesting to see
comparable developments in the use of dopamine and dopamine agonists. Dopamine
gained its place in the intensive care setting and in the acute treatment of CHF, because
of haemodynamic (and natriuretic) effects. later, positive effects of long term treatment
of CHF were reported with oral levodopa.
Expectations were high when an orally active, selective DA-l dopamine agonist,
fenoldopam, was developed. Hemodynamic effects in acute studies were indeed
impressive. However, its use in chronic treatment of hypertension and CHF proved to be
disappointing. This is supposed to be related to activation of the SNS and RAAS, not only
as a compensatory response to the vasodilation, but even due to a direct stimulating effect
on renin release. On the other hand, with the hemodynamically weaker and aselective
orally active dopamine agonist, ibopamine, positive results on exercise tolerance during
chronic treatment of CHF were found (DIMT study). In acute studies a fall in plasma
norepinephrine levels an a neutral or diminishing effect on the RAAS were observed.
This was the situation before the start of the studies described in this thesis.
rJy'e investigated not only the hemodynamic effects, but also whether the increase in renal
plasma flow (ERPF) and glomerular filtration rate (GFR), observed in patients with
congestive heart failure (CHF) during treatment with ibopamine, are due to specific renal
hemodymic effects or to systemic hemodynamic effects (chapter 3). We appreciated, that
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ibopamine caused a small but significant increase in both ERPF and GFR. However,
ibopamine increased cardiac ouQut and decreased systemic vascular resistance to a similar
extent and we found no change in the ratio renal blood flow / cardiac output. Therefore,
the renal effects of ibopamine with equal pre- and postglomerular vasodilation, appear to
be primarily due to its systemic hemodynamic effects. We also investigated in this study
whether the acute renal effects during treatment with ibopamine were also present after
longterm treatment. Acute on chronic administration of ibopamine also increased both
ERPF and GFR. The increase of ERPF after the acute on chronic administration of
ibopamine was less pronounced compared to the increase in ERPF after the acute
administration of ibopamine. No signs of tolerance were observed with respect to the
response of GFR during prolonged treatment with ibopamine. Furthermore in none of the
patients a deterioration of renal function was observed during prolonged treatment with
ibopamine. Apart from these renal and systemic hemodynamic effects we investigated the
acute and chronic neurohumoral effects of ibopamine treatment in these patients with mild
CHF. We observed that plasma renin activity (PRA) and plasma aldosterone remained
unchanged. However the acute administration of ibopamine lowered plasma
norepinephrine levels and these levels remained unchanged after the acute on chronic
administration of ibopamine.
Nowadays, ACEI are the cornerstone in the treatment of congestive heart failure and
also in the treatment of diabetic nephropathy and nephrotic syndrome. Many renal
hemodynamic and neurohumoral effects are shared by angiotensin converting enzymc
inhibitors (ACEI) and dopamine, while their mode of action is quite different. The
combination of ACEI and dopamine might have more pronounced and perhaps favorable
neurohumoral and renal effects. In chapter 4 we investigated therefore the effects of
addition of dopamine to an angiotensin converting enzyme inhibitors (ACEI) in healthy
volunteers. We observed that the addition of dopamine intusion to ACE-inhibition
enhances renal vasodilation probably by pre- but predominantly postglomerular
vasodilation, reflected by an increase in ERPF and a decrease in FF, without a change in
GFR- Furthermore, it promotes natriuresis without changing the renin angiotensin
aldosterone system (RAAS) or plasma norepinephrine levels in healthy volunteers.
Therefore studies in diseases like congestive heart failure, diabetic nephropathy and
nephrotic syndrome not only with the combination of ACEI with dopamine, but also with
orally available dopamine agonists are needed. They might not only show favorable renal
effects, but perhaps also a decrease in neurohumoral parameters.
As stated previously, much attention has been paid to neurohumoral effects in patients
with CHF. Especially plasma norepinephrine levels, as a reflection of sympathetic
neryous system activation, are correlated to the mortality rate in patients with CHF.
Therefore drugs that may decrease plasma norepinephrine levels could be of additional
value in the treatment of CHF. Presynaptic DA-2 dopaminergic and u-2 adrenergic
receptor stinulation in vitro decreases plasma norepinephrine levels.
In chapter 5 we used a standardised exercise test as a model for sympathetic
stimulation in normal man and investigated whether dopamine in different doses alone or








































plasma norepinephrine levels. Dopamine I pglkglmin infusion blunted the increase in
plasma norepinephrine levels during graded exercise compared to either placebo or
doparnine 3 prglkg/rnin infusion. We presume that for this dose of dopamine the inhibitory
effects of presynaptic DA-2 dopamine or a-2 adrenoceptor stimulation on norepinephrine
release predorninate. When dopamine is infused at an higher dose, 3 pglkgimin, the
inhibitory effects might be counteracted by uptake-1 inhibition or enhanced synthesis and
release of norepinephrine by dopamine. The increase in plasma norepinephrine levels
during graded exercise is augmented during infusion of dopamine cornbined with
dornperidone, which further supports the theory that DA-2 dopaminergic receptor
sti lnulation is important in the control of plasma norepinephrine levels. One might argue
that an increase in arm t'low during exercise plus dopamine might also lead to such a fall
in venous plasma norepinephrine l vels.
Therefore we used (chapter 6) a cold pressor test as a stimulus for the sympathetic
neryous system in a comparable study protocol as for the exercise test (chapter 5). A
cold pressor test wil l result in vasoconstriction and a fall in blood flow even in the
contralateral arm, in contrast to an exercise test. We observed that in healthy volunteers
doparnine I pglkgimin infusion blunts the increase in plasma norepinephrine levels during
a cold pressor test compared to either placebo or dopamine 3 pglkglmin infusion. The
addition of domperidone abolished the lowering effect of dopamine I pglkg/min, whereas
the addition of domperidone had no effect on dopamine 3 pglkglmin These results
support that only a low dose of dopamine (1 pglkglmín) might decrease plasma
norepinephrine levels in an activated sympathetic nervous system and that these effects
are probably not due to an increase in blood flow.
Doparnine is in general use in the intensive care unit or perioperatively. Low dose
dopamine. 1-4 pglkglmin, is usually given with the intention to maintain diuresis and
possibly renal function. However, whether renal function is influenced by dopamine
during mechanical venti lation with PEEP is not known yet, although it is nearly always
given for this reason.
In chapter 7 we shorved that dopamine in doses up to 4 pglkg/min increases renal
blood t-low (RBF) and GRF in a dose dependent way in these patients. However, the
increase in RBF can fully be ascribed to the increase in cardiac output.
At a dose of 8 pglkgimin, dopamine even decreases the fraction of the cardiac output
directed to the kidneys. Diuresis and natriuresis are increased by ciopamine in a dose
dependent way for all the doses used, and therefore probably independent of the renal
hemodynamic effects. So, when the goal is to obtain a maximal increase in RBF and
GFR.. with an additional increase in diuresis and sodium excretion, dopamine in a dose of
4 prglkgln;'in should be given. However, whether dopamine in a low dose may preserve
renal function in these and other patients, is still a matter of debate.
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